$9.150
-0.374 (-4.09%)收盤時
TLX 資訊
TLX 事件
Telix Pharmaceuticals Stock Down 9.9% to $10.06
Telix Pharmaceuticals is down -9.9%, or -$1.10 to $10.06.
Telix Pharmaceuticals Stock Down 10.1% to $10.03
Telix Pharmaceuticals is down -10.1%, or -$1.13 to $10.03.
Telix Confirms FY26 Revenue Exceeds $1B
Telix reaffirmed that FY26 revenue and other income is expected to be in excess of $1B, with revenue tracking in line with upper end of FY26 guidance of $950M-$970M plus $40M of other income. The Company has also revised its FY26 R&D expenditure guidance range to $240M to $260M.
Genomic Medicine CEO Expects Over 25% Revenue Growth in 2026
Christian Behrenbruch, Managing Director and Group CEO, stated, "Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality. We are pleased by the strong September exit run rate, supporting our confidence in delivering over 25% Precision Medicine revenue growth in 2026. We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base. During the quarter, we announced a transformative merger with ITM, creating a leading vertically integrated radiopharmaceutical company with one of the industry's broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities. This is aligned with our long-term growth strategy reinforcing our ability to reliably serve patients at scale."
Telix Pharmaceuticals Collaborates with Ekalia to Advance US Production of Astatine-211
Telix Pharmaceuticals and Ekalia, a joint venture between Ion Beam Applications and Framatome, announced a collaboration to advance scalable United States production of astatine-211, an alpha-emitting radioisotope being investigated for targeted alpha therapy. The collaboration brings together IBA's specialized alpha-beam cyclotron technology, Framatome's nuclear and isotope production expertise, and Telix's U.S. radiopharmacy and "last-mile" infrastructure, clinical portfolio and radiopharmaceutical development capabilities. The alliance expands into the U.S. the strategic partnership formed by IBA and Framatome in Europe to advance industrial-scale At production. The first installation at RLS Trevose is intended to establish a reproducible production model, with the potential for further rollout across the RLS network as demand develops.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。